casino game quest 2

nice88 apk download for android ios NEW YORK and LONDON , Dec. 11, 2024 /PRNewswire/ -- Pearl Diver Credit Company Inc. (NYSE: PDCC) (the "Company") has commenced an underwritten public offering of its Series A Preferred Stock Due 2029. Certain financial and other terms of the Series A Preferred Stock are to be determined by negotiations between the Company and the underwriters. Shares of the Series A Preferred Stock are rated 'BBB' by Egan-Jones Ratings Company, an independent rating agency. In addition, the Company plans to grant the underwriters a 30-day option to purchase additional shares of Series A Preferred Stock pursuant to the same terms and conditions. Shares of the Series A Preferred Stock are expected to be listed on the New York Stock Exchange and to trade thereon within 30 days of the original issue date under the ticker symbol "PDPA." Lucid Capital Markets, LLC ("Lucid"), B. Riley Securities, Inc. and Kingswood Capital Partners, LLC are acting as joint book-running managers and InspereX LLC and Janney Montgomery Scott LLC are acting as lead managers for the offering. The Company intends to use the proceeds from the offering to acquire investments in accordance with the investment objectives and strategies described in the prospectus supplement and for general working capital purposes. Investors should consider the Company's investment objectives, risks, charges and expenses carefully before investing. The preliminary prospectus, which has been filed with the Securities and Exchange Commission ("SEC"), contains this and other information about the Company and should be read carefully before investing. The information in the preliminary prospectus and this press release is not complete and may be changed. The preliminary prospectus and this press release are not offers to sell these securities and are not soliciting an offer to buy these securities in any state where such offer or sale is not permitted. A registration statement relating to these securities is on file with, but has not yet been declared effective by, the SEC. Copies of the preliminary prospectus (and the final prospectus, when available) may be obtained by writing to Lucid Capital Markets, LLC, 570 Lexington Avenue, New York, New York 10022, by calling Lucid toll-free at 646-362-0256 or by sending an e-mail to Lucid at prospectus@lucid.com . Copies also may be obtained on the SEC's website at www.sec.gov . Egan-Jones Ratings Company is a nationally recognized statistical rating organization (NRSRO). A security rating is not a recommendation to buy, sell or hold securities, and any such rating may be subject to revision or withdrawal at any time by the applicable rating agency. About Pearl Diver Credit Company Inc. Pearl Diver Credit Company Inc. (NYSE: PDCC) is an externally managed, non-diversified, closed-end management investment company. Its primary investment objective is to maximize its portfolio's total return, with a secondary objective of generating high current income. The Company seeks to achieve these objectives by investing primarily in equity and junior debt tranches of CLOs collateralized by portfolios of sub-investment grade, senior secured floating-rate debt issued by a large number of distinct US companies across several industry sectors. The Company is externally managed by Pearl Diver Capital LLP. For more information, visit www.pearldivercreditcompany.com . Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in the prospectus and the Company's other filings with the SEC. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release. NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE Investor Contact: Info@Pearldivercap.com UK: +44 (0)20 3967 8032 US: +1 617 872 0945 View original content to download multimedia: https://www.prnewswire.com/news-releases/pearl-diver-credit-company-inc-announces-offering-of-series-a-preferred-stock-302329464.html SOURCE Pearl Diver Credit Company Inc.

Ex-Colorado footballer Bloom dedicates time to fulfilling wishes for older adults

Posts Strong Adjusted EBITDA Margin ‎ 1 ‎ for Fiscal Year 2024 and Returns to Positive Sequential Growth in Fiscal Q4 2024 CINCINNATI, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (" Quipt " or the " Company ") QIPT QIPT , a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its fourth quarter and fiscal year 2024 financial results and operational highlights. These results pertain to the three months and year ended September 30, 2024 and are reported in U.S. Dollars. The Company no longer qualifies as a "foreign private issuer" as such term is defined in Rule 405 under the U.S. Securities Act of 1933, as amended, and Rule 3b-4 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which means that the Company, as of October 1, 2024, has been required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers. Accordingly, the Company is now required to prepare its financial statements filed with the Securities and Exchange Commission (" SEC ") in accordance with generally accepted accounting principles in the United States (" U.S. GAAP "), starting with the Company's fourth quarter and full year fiscal 2024 results. In addition, as required pursuant to section 4.3(4) of National Instrument 51-102 - Continuous Disclosure Obligations , the Company must restate and file under the Company's profile on SEDAR+ ( www.sedarplus.com ), ‎its interim financial reports for the fiscal year ended September 30, 2024 in accordance with U.S. GAAP, such interim financial reports having previously been prepared in accordance with the International Financial Reporting Standards (" IFRS "). Conference Call Quipt will host its Earnings Conference Call on Tuesday, December 17, 2024 at 10:00 a.m. (ET). Interested parties may participate in the call by dialing: +1 (844) 763-8274, or +1 (647) 484-8814. The live audio webcast can be found on the investor section of the Company's website through the following link: www.quipthomemedical.com . Following the conclusion of the call, a replay of the webcast will be available on the Company's website for at least the first year following the event. Financial Highlights : Revenue for fiscal year 2024 was $245.9 million compared to $211.7 million for fiscal year 2023, representing a 16.2% increase. Organic Growth 1 was approximately $7.1 million, or 3%. The transition from IFRS to U.S. GAAP resulted in a reduction of revenues for fiscal year 2023 of $10.1 million with a corresponding elimination of bad debt expense, resulting in no change to Adjusted EBITDA 1 or net loss. The comparison periods reflect this change. The pause of the Medicare 75/25 relief as of January 1, 2024, and the withdrawal of Medicare Advantage members due to the capitated agreement engaged with other providers in the industry negatively impacted revenue by approximately $5 million for fiscal year 2024. Moreover, the estimated impact on the cash collections of accounts receivable from the February 21, 2024 cyberattack on Change Healthcare is estimated at approximately $3 million. Recurring Revenue‎ 1 for fiscal year 2024 was very strong and was approximately 78% of total revenue, driven by the growth in the Company's re-supply platform. Adjusted EBITDA for fiscal year 2024 was $57.9 million (23.5% margin), compared to Adjusted EBITDA for fiscal year 2023 of $50.6 million (23.9% margin), representing a 14.3% increase. Net income (loss) for fiscal year 2024 was ($6.8) million, or ($0.16) per diluted share, compared to ($2.8) million, or ($0.07) per diluted share for fiscal year 2023. Revenue for Q4 2024 was $61.3 million compared to $59.6 million for Q4 2023, representing a 3% increase. Sequential organic revenue growth was approximately 1%. Adjusted EBITDA for Q4 2024 was $13.4 million (21.8% margin) compared to $14.7 million (24.6% margin) for Q4 2023, representing an 8.8% decrease. Cash flow from operations was $35.4 million for fiscal year 2024, compared to $37 million for fiscal year 2023. The Company reported $16.2 million of cash on hand as of September 30, 2024, compared to $14.4 million as of June 30, 2024. Total credit availability of $34.7 million as of September 30, 2024 with $13.7 million available towards a revolving credit facility and $21 million available pursuant to a delayed-draw term loan facility. The Company maintains a conservative balance sheet with Net Debt to Adjusted EBITDA Leverage Ratio 1 of 1.6x. Operational Highlights : The Company's customer base increased 4% year over year to approximately 153,000 unique patients served in Q4 2024 from approximately 147,000 unique patients in Q4 2023. Compared to approximately 754,000 unique set-ups/deliveries in fiscal year 2023, the Company completed approximately 854,000 unique set-ups/deliveries in fiscal year 2024, an increase of 13%. This includes approximately 480,000 respiratory resupply set-ups/deliveries for fiscal year 2024, compared to approximately 396,000 for fiscal year 2023, an increase of 21%, which the Company credits to its continued use of technology and centralized intake processes. The Company's resupply program is a major proponent of the 78% Recurring Revenue base as the Company has significantly scaled, now representing 51%, of the Recurring Revenue mix, driving higher margin revenue and now consists of 172,000 patients as of September 30, 2024, compared to 169,000 patients as of September 30, 2023. Positive sequential organic revenue growth of 1% in Q4 2024, signaling a gradual recovery from challenges faced throughout the year. Consistent demand and referral patterns across all major product categories. The Company has approximately 314,000 unique active patients that were served at least once in the last ‎twelve months, approximately 36,000 referring physicians, and approximately 135 locations.‎ Management Commentary : "Our results for fiscal 2024 reflect the resilience of our business and the scalability of our operating model," said Gregory Crawford, Chairman and CEO of Quipt. "Despite facing unique challenges this year, we delivered record revenue, positive year-over-year organic growth and maintained a strong Adjusted EBITDA Margin 1 . This performance underscores the strength of our diversified product offering, go-to-market strategy and the adaptability of our team. As we look ahead to calendar 2025 and beyond, we have a high confidence level in our ability to return to consistent, historical organic growth levels. Our focus remains on leveraging the demographic trends such as the aging population and increasing prevalence of chronic respiratory conditions, while expanding our referral base through our growing salesforce and strategic investments. By combining these initiatives with our disciplined approach to inorganic growth, we aim to strengthen our market position and deliver sustained growth. The demand for in-home respiratory solutions continues to grow, and our ability to provide comprehensive, patient-centric care positions us well to capture this opportunity. We remain committed to operational excellence, enhancing our recurring revenue base, and executing on our growth roadmap to drive both scale and profitability. With a strong balance sheet, we are well-equipped to allocate capital toward strategic opportunities, while also investing in organic growth to build long-term shareholder value." "Our financial performance in fiscal 2024 highlights the stability of our core operations," added Hardik Mehta, Chief Financial Officer of Quipt. "In the fourth quarter, we returned to positive sequential organic revenue growth, which demonstrates the regained momentum in our business. As we move into calendar 2025, we are seeing strengthening trends across our major product categories, supported by solid referral activity and steady demand for our end-to-end respiratory care solutions. These factors give us confidence that we will return to consistent, historical organic growth levels in calendar 2025. With a scalable operating model, a focused growth strategy, and favorable demographic tailwinds, we are well-positioned to seize the opportunities in front of us." ABOUT QUIPT HOME MEDICAL CORP. The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company's organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient's services, and making life easier for the patient. Forward-Looking Statements Certain statements contained in this press release constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or "forward-looking information" as such term is ‎‎‎‎‎‎defined in applicable Canadian securities legislation (collectively, "forward-looking statements"). The words "may", "would", "could", "should", "potential", ‎‎‎‎‎‎‎"will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect", "outlook", or the negatives thereof or variations of such words, and similar expressions ‎‎‎‎‎as ‎they relate to the Company, including: the Company anticipating a return to historical organic growth levels; are intended to ‎identify forward-looking information. All statements ‎other ‎than ‎statements of ‎‎historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-‎looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the ‎Company's ‎current ‎views and ‎‎intentions with respect to future ‎events, and current information available to the ‎Company, and ‎are ‎subject to ‎‎certain risks, uncertainties and ‎assumptions, including, without limitation: the ‎Company successfully identifying, ‎‎‎negotiating and ‎completing additional acquisitions; operating and other financial metrics maintaining their ‎‎current trajectories, the Company not being impacted by any further external and unique events like the Medicare ‎‎75/25 rate cut and the Change Healthcare cybersecurity incident for the remainder of the calendar year and in 2025; and the ‎Company not being subject to a material change to it cost structure. Many ‎factors could cause the actual ‎results, ‎‎performance or achievements that may be ‎expressed ‎or implied by such ‎forward-looking statements to ‎vary from ‎‎those described herein should one or more ‎of these ‎risks or ‎uncertainties materialize. Examples of such ‎risk ‎factors ‎include, without limitation: risks related ‎to credit, market ‎‎‎(including equity, commodity, foreign exchange ‎and interest ‎rate), ‎liquidity, operational ‎‎(including technology ‎and ‎infrastructure), reputational, insurance, ‎strategic, ‎regulatory, legal, ‎environmental, and ‎capital adequacy; the ‎‎general business and economic conditions in ‎the regions ‎in which the ‎Company operates; ‎the ability of the ‎‎Company to execute on key priorities, including the ‎successful ‎completion of ‎acquisitions, ‎business retention, and ‎‎strategic plans and to attract, develop and retain ‎key ‎executives; difficulty ‎integrating ‎newly acquired businesses; ‎‎the ability to implement business strategies and ‎‎pursue business opportunities; low ‎profit ‎market segments; ‎‎disruptions in or attacks (including cyber-attacks) on ‎‎the Company's information ‎technology, ‎internet, network ‎‎access or other voice or data communications systems or ‎‎services; the evolution of ‎various types ‎of fraud or other ‎‎criminal behavior to which the Company is exposed; the ‎‎failure of third parties to ‎comply with ‎their obligations to ‎‎the Company or its affiliates; the impact of new and ‎‎changes to, or application of, ‎current ‎laws and regulations; ‎‎decline of reimbursement rates; dependence on few ‎‎payors; possible new drug ‎discoveries; a ‎novel business ‎model; ‎dependence on key suppliers; granting of permits ‎‎and licenses in a highly ‎regulated ‎business; legal proceedings and litigation, including as it relates to the civil ‎‎investigative demand ("CID") ‎received from the Department of Justice; ‎increased competition; ‎changes in ‎foreign currency rates; ‎increased ‎‎funding costs and market volatility due to ‎market illiquidity and ‎competition for ‎funding; the ‎availability of funds ‎‎and resources to pursue operations; ‎critical accounting ‎estimates and changes ‎to accounting ‎standards, policies, ‎‎and methods used by the Company; the Company's status as an emerging growth company and a smaller reporting company; the occurrence of ‎natural and unnatural ‎catastrophic ‎events or health epidemics or concerns; as well as those risk factors ‎discussed or ‎‎referred to ‎in the Company's disclosure ‎documents filed with ‎United States Securities and Exchange ‎Commission ‎‎(the "SEC") and ‎available at www.sec.gov , including the Company's most recent Annual Report on Form 10-K, and with ‎the securities ‎regulatory authorities in certain provinces of ‎Canada and ‎‎‎available at www.sedarplus.com . Should any ‎factor affect ‎the Company in an unexpected manner, or ‎should ‎‎‎assumptions underlying the forward-looking ‎statement prove ‎incorrect, the actual results or events may ‎differ ‎‎‎materially from the results or events predicted. ‎Any such forward-‎looking statements are expressly qualified ‎in their ‎‎‎entirety by this cautionary statement. Moreover, ‎the Company ‎does not assume responsibility for the ‎accuracy or ‎‎‎completeness of such forward-looking ‎statements. The ‎forward-looking statements included in this ‎press release ‎‎‎is made as of the date of this press ‎release and the ‎Company undertakes no obligation to publicly ‎update or revise ‎‎‎any forward-looking statements, ‎other than as ‎required by applicable law‎.‎ Non-GAAP Financial Measures This press release refers to "Organic Growth", "Recurring Revenue", "Adjusted EBITDA", "Adjusted EBITDA Margin" and "Adjusted Net Debt to Adjusted EBITDA Leverage Ratio", which are non-GAAP financial measures that do not have standardized meanings prescribed by U.S. GAAP. The ‎Company's presentation of these financial measures may not be comparable to similarly titled measures used by ‎other companies. These financial measures are intended to provide additional information to investors concerning ‎the Company's performance.‎ Organic Growth is calculated as the increase in revenues of $34.2 million, less the revenues contributed by acquisitions of $27.1 million, divided by fiscal year 2023 revenue of $211.7 million, or 3%. Recurring Revenue for fiscal 2024 is calculated as rentals of medical equipment of $94.3 million plus sales of respiratory resupplies of $96.5 million for a total of $190.8 million, divided by total revenues of $245.9 million, or 78%. Adjusted EBITDA is calculated as net loss, and adding back depreciation and amortization, right-of-use operating lease amortization and interest, interest expense, net, provision (benefit) for income taxes, professional fees related to civil investigative demand and loss of foreign private issuer status, stock-based compensation, acquisition-related costs, loss on extinguishment of debt, gain (loss) on foreign currency transactions, change in fair value of derivative liability – interest rate swap, and share of loss of equity method investment. The following table shows our non-GAAP measure, Adjusted EBITDA, reconciled to our net income (loss) for the ‎following indicated periods‎ (in $millions)‎:‎ For the three For the three For the For the months ended months ended year ended year ended September September September September 30, 2024 30, 2023 30, 2024 30, 2023 Net loss $ (3.2 ) $ (1.3 ) $ (6.8 ) $ (2.8 ) Add back: Depreciation and amortization 11.5 10.9 44.6 36.1 Right-of-use operating lease amortization and interest 1.4 1.5 6.0 5.1 Interest expense, net 1.5 1.6 6.4 5.5 Provision (benefit) for income taxes (0.3 ) 0.1 0.1 0.1 Professional fees related to CID 0.9 — 3.1 — Professional fees related to loss of foreign private issuer status 0.2 — 0.2 — Stock-based compensation 0.3 1.4 2.5 5.3 Acquisition-related costs 0.0 0.1 0.4 1.3 Loss on extinguishment of debt — — — 0.0 Gain (loss) on foreign currency transactions (0.2 ) 0.3 (0.0 ) (0.1 ) Change in fair value of derivative liability - interest rate swap 1.1 — 1.1 — Share of loss in equity method investment 0.1 0.1 0.3 0.1 Adjusted EBITDA $ 13.4 $ 14.7 $ 57.9 $ 50.6 Adjusted EBITDA Margin for fiscal 2024 is calculated as Adjusted EBITDA of $57.9 million divided by revenue of $245.9 million, or 23.5%. Q4 2024 is calculated as Adjusted EBITDA of $13.4 million divided by revenue of $61.3 million, or 21.8%. Net Debt to Adjusted EBITDA Leverage Ratio is calculated as Net Debt, divided by (Adjusted EBITDA for Q4 times four), and is reconciled as follows (in $millions): As of and for the three months ended ended September 30, 2024 Senior credit facility, principal $ 69.2 Equipment loans 12.9 Lease liabilities 19.2 Cash (16.2 ) Net Debt 85.1 Adjusted EBITDA for Q4 times four $ 53.6 Net Debt to Adjusted EBITDA Leverage Ratio 1.6x For further information please visit our website at www.Quipthomemedical.com , or contact: Cole Stevens VP of Corporate Development Quipt Home Medical Corp. 859-300-6455 cole.stevens@myquipt.com Gregory Crawford Chief Executive Officer Quipt Home Medical Corp. 859-300-6455 investorinfo@myquipt.com ___________________________________ 1 Non-GAAP financial measure or ratio. See "Non-GAAP Financial Measures".‎ © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Mickey, Minnie, Goofy and Wemby

Effective Cockroach Pest Control Solutions Available Across Sydney, NSW

Na Evropském dni inovací 2024 společnosti Huawei se hovořilo o spolupráci a technologickém potenciálu EvropyPearl Diver Credit Company Inc. Announces Offering of Series A Preferred Stock

Figure 1 Site Rendering of NOVONIX’s New Facility BRISBANE, Australia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX” or “the Company”), a leading battery materials and technology company, announced today a conditional commitment to NOVONIX through one if its wholly-owned U.S.-based subsidiaries (“Borrower”), from the U.S. Department of Energy (“DOE”) through the Loan Programs Office (“LPO”) for a direct loan of up to US$754.8 million ($692 million in principal and $62.8 million in capitalized interest) to be applied towards partially financing a proposed new facility in Chattanooga, Tennessee (the “New Facility”). The proposed financing is being offered under the DOE LPO’s Advanced Technology Vehicles Manufacturing (“ATVM”) Loan Program. If finalized, the loan would be applied towards partially financing the construction of the New Facility in Chattanooga, Tennessee, to manufacture synthetic graphite primarily for use in electric vehicle (“EV”) batteries. At full capacity, the new facility is expected to produce approximately 31,500 tonnes per annum (“tpa”) of synthetic graphite, which can support the production of lithium-ion batteries for approximately 325,000 EVs each year. China currently has over 95% market share for battery grade graphite 1 . The new facility is expected to reach full production capacity by the end of 2028 and is anticipated to create 450 full-time operational jobs and 500 construction jobs. Dr. Chris Burns, CEO of NOVONIX said, “This announcement is the culmination of years of hard work and is another critical milestone for our anode materials business towards our target production of 150,000 tpa in North America. This conditional commitment from the government to invest in our new facility continues to underscore the focus on localizing critical materials in the battery supply chain, such as graphite. Recent announcements from China to further scrutinize the export of battery-grade graphite to the United States highlight the importance of domestic production of high-performance, battery-grade synthetic graphite. Our offtake agreements with strong partners have strengthened our leadership in onshoring the synthetic graphite supply chain in North America and supporting the path towards U.S. energy independence.” This year, NOVONIX has signed binding offtake agreements to supply synthetic graphite to Panasonic Energy 2 , Stellantis 3 , and PowerCo 4 . To meet this demand, the Company has previously discussed plans to build a new facility in the southeastern United States which could expand up to 75,000 tpa or production capacity. This proposed ATVM Program loan would support the construction of the first phase of the New Facility and the initial production capacity of 31,500 tpa. NOVONIX plans to subsequently expand the production capacity of this site to its target of 75,000 tpa of synthetic graphite production, any such expansion being dependent on customer demand and access to additional financing. NOVONIX’s Riverside facility, also located in Chattanooga, is poised to become the first large-scale production site dedicated to high-performance synthetic graphite for the battery sector in North America. It is slated to begin commercial production in 2025, with plans to grow output to 20,000 tpa to meet current customer commitments. Previously, the Company announced that the DOE’s Office of Manufacturing and Energy Supply Chains (“MESC”) awarded the Company a US$100 million grant 5 and that it was selected for a US$103 million investment tax credit 6 towards the funding of the Riverside facility. Key terms of the DOE’s conditional commitment, including those set forth in a non-binding term sheet attached to the conditional commitment letter signed by the DOE, NOVONIX and the Borrower, include: The loan is for a maximum amount of US$754.8 million, which includes up to US$692.0 million in principal and up to US$62.8 million in capitalized interest and will be structured in two tranches based on a phased completion of infrastructure and production lines from a total eligible investment of US$943.6 million. The loan will be comprised of two primary tranches that will have terms of 15 years and 10 years, respectively, from the date of first payment of each. The first tranche will be to support the site and infrastructure for the New Facility and 21,000 tpa of production capacity, while the second tranche will support an additional 10,500 tpa of production capacity. An additional tranche to fund eligible project costs will be subject to repayment upon receipt of any proceeds derived from the monetization of any tax credit received by the Company or the Borrower related to the New Facility under the Qualifying Advanced Energy Project Allocation Program. The loan will be guaranteed by the Company and secured by a first priority security interest in all assets of the Borrower, equity interests in and, with certain exceptions, assets of certain of NOVONIX’s existing subsidiaries. Each advance of loan proceeds will have a separate interest rate set by the Federal Financing Bank under the general supervision of the Secretary of Treasury at the time that the respective advance is made. While this conditional commitment demonstrates DOE’s intent to finance the New Facility, DOE must complete an environmental review, and the Company must satisfy certain technical, commercial, legal, environmental, and financial conditions before DOE can decide whether to enter into definitive financing documents and fund the loan. A binding loan agreement from DOE is also subject to the satisfactory completion of due diligence by DOE, satisfaction of conditions precedent specified in the term sheet, approval of the NOVONIX Board, receipt of required governmental and third-party consents, and the negotiation and execution of binding loan documents. Once binding loan documents have been signed, NOVONIX and the Borrower will need to satisfy certain conditions precedent prior to loan closing, and / or prior to first and subsequent advances of loan proceeds. This announcement has been authorised for release by Admiral Robert J Natter, USN Ret., Chairman. About NOVONIX NOVONIX is a leading battery technology company revolutionizing the global lithium-ion battery industry with innovative, sustainable technologies, high-performance materials, and more efficient production methods. The Company manufactures industry-leading battery cell testing equipment, is growing its high-performance synthetic graphite material manufacturing operations, and has developed a patented all-dry, zero-waste cathode synthesis process. Through advanced R&D capabilities, proprietary technology, and strategic partnerships, NOVONIX has gained a prominent position in the electric vehicle and energy storage systems battery industry and is powering a cleaner energy future. To learn more, visit us at www.novonixgroup.com or on LinkedIn and X . For NOVONIX Limited Scott Espenshade, ir@novonixgroup.com (investors) Stephanie Reid, media@novonixgroup.com (media) Cautionary Note Regarding Forward-Looking Statements This communication contains forward-looking statements about the Company and the industry in which we operate. Forward-looking statements can generally be identified by use of words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or other similar expressions. Examples of forward-looking statements in this communication include, among others, statements we make regarding our target production capacity and commencement of commercial production at our Riverside facility, our plans to build a new production facility and achieve initial and total production capacities, and our efforts to finance this new production facility with a loan from the LPO. We have based such statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Such forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, among others, the timely deployment and scaling of our furnace technology, our ability to meet the technical specifications and demand of our existing and future customers, the accuracy of our estimates regarding market size, expenses, future revenue, capital requirements, needs and access for additional financing, the availability and impact and our compliance with the applicable terms of government support, including the DOE MESC grant and, if a definitive agreement is executed and the loan is funded, the LPO loan, our ability to satisfy the conditions precedent to our entering into definitive loan documents and to the DOE’s funding the LPO loan and, if the loan is obtained, our ability to comply with the restrictions and obligations under the loan documents, our ability to obtain patent rights effective to protect our technologies and processes and successfully defend any challenges to such rights and prevent others from commercializing such technologies and processes, and regulatory developments in the United States, Australia and other jurisdictions. These and other factors that could affect our business and results are included in our filings with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s most recent annual report on Form 20-F. Copies of these filings may be obtained by visiting our Investor Relations website at www.novonixgroup.com or the SEC’s website at www.sec.gov. Forward-looking statements are not guarantees of future performance or outcomes, and actual performance and outcomes may differ materially from those made in or suggested by the forward-looking statements contained in this communication. Accordingly, you should not place undue reliance on forward-looking statements. Any forward-looking statement in this communication is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law. 1 Benchmark Minerals Intelligence Anode Price Assessment September 2024 2 Panasonic Energy and NOVONIX Sign Binding Off-Take Agreement - NOVONIX 3 NOVONIX and Stellantis Sign Binding Offtake Agreement - NOVONIX 4 NOVONIX and PowerCo SE Sign Binding Offtake Agreement - NOVONIX 5 NOVONIX Finalizes US$100 Million Grant Award from U.S. Department of Energy - NOVONIX 6 U.S. Government Selects NOVONIX to Receive US$103 Million in Qualifying Advanced Energy Project Tax Credits - NOVONIX A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9a660b84-f19e-4636-b981-d532b2029ace

My beautiful daughter died after relentless online bullies told her to kill herself...we need under 16 ban like AustraliaScholastic Corporation Announces Third Quarter Dividend3D Metrology Market worth $15.01 Billion by 2029, at a CAGR of 6.2% 12-16-2024 10:38 PM CET | Associations & Organizations Press release from: ABNewswire 3D Metrology Market The global 3D Metrology Market is anticipated to grow from USD 11.13 billion in 2024 to USD 15.01 billion by 2029 expanding at a compound annual growth rate (CAGR) of 6.2% during the forecast period. The report "3D Metrology Market [ https://www.marketsandmarkets.com/Market-Reports/3d-metrology-market-203080758.html?utm_source=abnewswire.com&utm_medium=PaidPR&utm_campaign=3dmetrologymarket ] by Coordinate Measuring Machine (CMM), Optical Digitizer and Scanner (ODS), Form Measurement Equipment, X-ray and CT Equipment, Video Measuring Machine (VMM) and 3D Automated Optical Inspection System - Global Forecast to 2029" The global 3D metrology market was estimated to be valued at USD 11.13 billion in 2024 and is projected to reach USD 15.01 billion by 2029; it is expected to register a CAGR of 6.2% during the forecast period. Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203080758 [ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203080758&utm_source=abnewswire.com&utm_medium=PaidPR&utm_campaign=3dmetrologymarket ] Browse 228 market data Tables and 69 Figures spread through 357 Pages and in-depth TOC on "3D Metrology Market" View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/3d-metrology-market-203080758.html [ https://www.marketsandmarkets.com/Market-Reports/3d-metrology-market-203080758.html?utm_source=abnewswire.com&utm_medium=PaidPR&utm_campaign=3dmetrologymarket ] Image: https://www.marketsandmarkets.com/Images/3d-metrology-market.webp [ https://www.marketsandmarkets.com/Market-Reports/3d-metrology-market-203080758.html?utm_source=abnewswire.com&utm_medium=PaidPR&utm_campaign=3dmetrologymarket ] Increasing demand for quality control in various end-use industries, emergence of 5G and IoT-enabled manufacturing, growing adoption of Industry 4.0, rising popularity of AI-based metrology tools, shift from labor-intensive manual inspections to advanced automated optical inspection systems, and growing application of big data analytics in metrology industry are the major factors driving the overall market growth. By CMM Type, bridge CMM segment to account for the largest market share in 2029. The bridge CMM segment is expected to lead the market during the forecast period. Bridge CMMs dominate the 3D metrology market due to their superior precision, reliability, and ability to handle diverse measurement tasks, making them ideal for industries requiring meticulous quality control of medium to large-sized components. In addition, better rigidity and higher accuracy are the major factors for adopting bridge CMMs for 3D metrology. Nikon provides bridge CMMs to PMS Diecasting Ltd. (UK) for inspection, thus enabling faster product-to-market and reduced development costs. By End-use Industry, medical segment is expected to exhibit the highest CAGR between 2024 and 2029. The medical end-use industry is expected to expand at the highest CAGR in the 3D metrology market. This can be attributed to the requirement for precision while developing implants, prosthetics, and surgical tools. As the number of minimally invasive operations and personal medical devices increases, there is a greater emphasis on improved measuring equipment. Furthermore, an increased focus on quality and safety has also encouraged the use of improved measurement systems in the medical industry. North America to hold the second-largest share in the market from 2024 to 2029. 3D metrology market in North America is predicted to have the second-largest market share throughout the forecast period due to significant growth in the aerospace and military industries, both of which require high levels of precision and quality. The presence of advanced industries and the ongoing investments in R&D of 3D measurement technologies have contributed to the growth of 3D metrology. The automobile sector, particularly in the US, has increased demand as production of electric vehicles has increased, necessitating the use of high-grade metrology systems for assembly and inspection purposes. Companies established in North America, such as FARO (US), KLA Corporation (US), InnovMetric Software (Canada) and Creaform (Canada), contribute to the region's growth. Key Players- The key companies offering 3D metrology solutions include Hexagon AB (Sweden), ZEISS Group (Germany), FARO (US), Mitutoyo Corporation (Japan), KEYENCE CORPORATION (Japan), KLA Corporation (US), Renishaw plc (UK), and Nikon Corporation (Japan) among others. Media Contact Company Name: MarketsandMarkets Trademark Research Private Ltd. Contact Person: Mr. Rohan Salgarkar Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=3d-metrology-market-worth-1501-billion-by-2029-at-a-cagr-of-62 ] Phone: 18886006441 Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 City: Delray Beach State: Florida Country: United States Website: https://www.marketsandmarkets.com/Market-Reports/3d-metrology-market-203080758.html This release was published on openPR.

SANTA CRUZ, Calif. (AP) — Two people were rescued when a California pier partially collapsed and fell into the ocean Monday as the state's central coast was pounded by heavy surf from a major storm expected to bring hurricane-force winds to the seas off the Pacific Northwest. Residents were warned to stay away from low-lying areas near the beaches around the Santa Cruz Wharf, about 70 miles (112 kilometers) south of San Francisco. “You are risking your life, and those of the people that would need to try and save you by getting in or too close to the water,” the National Weather Service's Bay Area office said on the social platform X. Lifeguards rescued two people from the water and a third person was able to swim to safety, the Santa Cruz Fire Department said on Instagram. Their conditions were unknown. Coastal roads in Santa Cruz were closed following the pier's partial collapse, city officials said. Gov. Gavin Newsom's has been briefed and the state's Office of Emergency Services is coordinating with local officials, his office said. Ocean swells along California's central coast could reach 26 feet (8 meters) as the Pacific storm gains strength through Monday, the weather service said. “A rapidly developing storm will bring hurricane force winds to the areas well offshore of the Pacific Northwest tonight,” the weather service's Ocean Prediction Center said on X. Winds off Oregon and Washington could peak near 80 mph (130 kph) and seas will build over 30 feet (9.1 meters), forecasters said. The Santa Cruz Wharf collapse Monday came about a year after the Seacliff State Beach pier just down the coast was battered beyond repair by a heavy winter storm. Copyright 2024 The Associated Press . All rights reserved. This material may not be published, broadcast, rewritten or redistributed.The NBA has signed a multimillion-dollar agreement to organize preseason games in Macau next October, returning American pro basketball to China after a five-year political hiatus. In 2019, Beijing banned NBA games after a player supported Hong Kong’s' pro-democracy demonstrations against the Chinese government. VOA Mandarin reports on the economic and political angles related to the return of the popular sport to Chinese stadiums. Click here for the full story in Mandarin.

No. 5 UCLA snaps No. 1 South Carolina's 43-game win streakBOULDER, Colo. — A 72-year-old lifelong Colorado fan with end-stage kidney failure waited to the side of the field in his wheelchair for Travis Hunter and the rest of the Buffaloes. One by one, players strolled over and signed a football for Riley Rhoades, his face lighting up with each signature. Standing close by and taking in the scene was Jeremy Bloom. He's become a wish facilitator for older adults. Bloom, the former Colorado wide receiver and Olympic freestyle skier, started the Wish of a Lifetime foundation in 2008, which has made thousands of aspirations turn into reality for older adults. The list of granted wishes range from taking veterans back to the beaches of Normandy to helping late-in-life authors publish a book. He's staged concerts for musicians, assisted some in daredevil feats such as jumping out of an airplane and even lined up a meeting between an Olympic medalist and former President Barack Obama. For Rhoades, his wish was simply to return to Folsom Field again, the place where he used to have season tickets but hasn't attended a game since 2004. "Everybody has somebody in their life —a grandparent, friend, neighbor — at that age where you wish you had more resources to help," said Bloom, whose college career was cut short two decades ago when the NCAA denied his reinstatement to play football and still ski professionally after receiving endorsement money to fuel his Olympic dreams. "Nothing can compare to seeing someone else's eyes light up because you helped make their dream come true." The foundation is a tribute to his grandparents. But the concept began to take root when he was a teenager. He was in Japan for a World Cup freestyle skiing competition when a woman tried to hop on a crowded bus. There was no room, but everyone in front rose from their seats to make space. That stuck with him, along with seeing these acts of kindness for older adults all over Europe and Asia as he traveled. An idea formed — bring that same level of appreciation to the United States, with a wish-granting element. Bloom's organization has been a charitable affiliate of AARP since 2020. It was the yearning of Rhoades that brought the two of them to Folsom Field last weekend. Rhoades, who had season tickets at Colorado for 27 years, wanted to see the Buffaloes in person after watching the team's resurgence on television. A few years ago, Rhoades, who was born with spina bifida, was diagnosed with end-stage renal failure. Being among the 54,646 fans Saturday stirred up plenty of emotions for Rhoades, as he watched the 16th-ranked Buffaloes (8-2, 6-1 Big 12, No. 16 CFP) beat Utah. Colorado remains in the race for not only a conference title but a spot in the College Football Playoff. "It's just great to be back here again," Rhoades said as he pointed out the section where he used to watch games. "It's just ... so cool." For Bloom, the success that coach Deion Sanders has brought to the program means more reunions with teammates as they pass through town. "I've been through many years where nobody comes to visit," Bloom said. "It's fun that Boulder has become the epicenter of college football." Leading the way for Colorado this season have been quarterback Shedeur Sanders and two-way star Hunter, who's the Heisman Trophy frontrunner. But what particularly pleases Bloom is that Sanders, Hunter and the rest of college football players are able to finally profit through name, image and likeness. In his day, Bloom got caught in the NCAA crosshairs for wanting to play both sports and to have sponsors in one (skiing) so he could fund his Olympic aspirations. How time have changed. "I'm just really grateful that this generation of athletes gets to monetize their skills and ability," said Bloom, who finished sixth in moguls at the 2006 Winter Games in Italy. "It's the right thing." He's thrown his passion into fulfilling wishes such as learning ballet, riding in a Formula 1 pace car or taking a flight in a fighter jet. He's also helped reconnect families and friends, including a reunion for a trio of centenarian sisters who hadn't seen each other in more than a decade. This granted wish has stuck with Bloom: A person in Alabama wasn't able to travel after being diagnosed with end-of-life emphysema. So he asked for postcards to be sent, just to learn what made someone's town so special. He received 2,000 postcards from 26 different countries. "There's no end to the things that they've done for us in the world," Bloom said of older adults. "We're one of the organizations that reminds them that their dreams still do matter and that we still appreciate them and we cherish them." Be the first to know Get local news delivered to your inbox!

FARMINGDALE, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo” or the "Company”) today announced financial results for the fiscal first quarter ended October 31, 2024. First Quarter Highlights Enzo Biochem, Inc. has operated as a life sciences company for over 45 years. The primary business of Enzo today is conducted through its Life Sciences division, Enzo Life Sciences, which focuses on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins. The Company's proprietary products and technologies play central roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. The Company monetizes its technology primarily via sales through our global distribution network and licensing. For more information, please visit enzo.com or follow Enzo Biochem on X and LinkedIn . Forward-Looking Statements Except for historical information, the matters discussed in this release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues and expenses, which are dependent on a number of factors outside of the control of the Company, including, inter alia, the markets for the Company's products, cost of goods sold, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company's Form 10-K for the fiscal year ended July 31, 2024. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release. Enzo Biochem Contacts For Enzo Biochem: Patricia Eckert, Chief Financial Officer Enzo Biochem 631-755-5500 [email protected] Use of Non-GAAP Financial Measures by Enzo The non-GAAP financial measures contained in this press release (including, without limitation, Adjusted net loss, EBITDA, and Adjusted EBITDA) are not GAAP measures of the Company's financial performance or liquidity and should not be considered as alternatives to net income (loss) as a measure of financial performance or cash flows from operations as measures of liquidity, or any other performance measure derived in accordance with GAAP. A reconciliation of such non-GAAP measures is included in the presentation of the Company's financial results for the quarter ended October 31, 2024 contained herein and is also available in the investor relations section of the Company's website ( https://www.enzo.com ). The Company believes the presentation of these non-GAAP measures provides useful additional information to investors because they provide information consistent with that on which management evaluates the financial performance of the Company. The Company manages its business based on its operating cash flows. It refers to EBITDA as its primary indicator of performance and refers to Adjusted EBITDA to further exclude items of a non-recurring nature. It is reasonable to expect that one or more excluded items will occur in future periods, though the amounts recognized can vary significantly from period to period. You are encouraged to evaluate each adjustment used to determine a non-GAAP financial measure and the reasons management considers it appropriate for supplemental analysis. Our presentation of these measures should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. We refer you to the tables attached to this press release, which includes reconciliation tables of GAAP net loss to Adjusted net loss and GAAP net loss to EBITDA and Adjusted EBITDA. (unaudited) (unaudited) Adjusted EBITDA $ (2,640 )Met Éireann forecast wet weekend with drop in temperatures next week

Effective Cockroach Pest Control Solutions Available Across Sydney, NSW 12-16-2024 10:34 PM CET | Associations & Organizations Press release from: ABNewswire Cockroach Pest Control Sydney, a leading pest control company based in Sydney, NSW, offers comprehensive solutions for cockroach infestations across residential, commercial, strata, and industrial properties. With a focus on safety and effectiveness, the company employs trained professionals who utilize the latest technology and environmentally friendly methods to ensure thorough extermination and prevention of cockroaches. Sydney, NSW - Cockroach Pest Control Sydney, a leading pest control company, is proud to announce its comprehensive range of services designed to combat cockroach infestations in residential, commercial, strata, and industrial properties throughout Sydney. With a commitment to effective and safe pest management, the company offers tailored solutions that address the unique challenges posed by cockroaches in various environments. Cockroaches are not only a nuisance but also pose significant health risks. They are known carriers of diseases and can contaminate food sources. The humid climate of Sydney creates an ideal breeding ground for these pests, making timely intervention essential. Cockroach Pest Control Sydney employs a team of highly trained professionals equipped with the latest technology and methods to ensure effective extermination and prevention of cockroach infestations. For more details visit us at https://cockroachpestcontrol.sydney . Residential Services For homeowners in Sydney, Cockroach Pest Control Sydney provides thorough inspections and customized treatment plans. The process begins with identifying the type of cockroach present and assessing the extent of the infestation. Following this assessment, a targeted extermination strategy is implemented. This may include the use of baits, traps, and environmentally friendly insecticides that are safe for both children and pets. Regular follow-up visits are also offered to ensure that the problem does not recur. Commercial Solutions Businesses in Sydney face unique challenges when it comes to pest control. Cockroach infestations can lead to significant reputational damage and health code violations. Cockroach Pest Control Sydney understands these risks and offers specialized services for commercial establishments, including restaurants, cafes, offices, and retail spaces. The company works discreetly to minimize disruption to business operations while ensuring that all pest control measures comply with local regulations. Strata Management Strata properties often require coordinated pest control efforts due to shared spaces and multiple units. Cockroach Pest Control Sydney collaborates with strata managers to develop comprehensive pest management plans that address the needs of all residents. This includes regular inspections, preventive treatments, and educational resources for residents on how to minimize attractants that lead to infestations. Industrial Applications Industrial facilities present unique challenges for pest control due to their size and operational complexities. Cockroach Pest Control Sydney offers tailored solutions for warehouses, factories, and distribution centers. The team conducts thorough assessments of the premises to identify potential entry points and breeding sites. Customized treatment plans are then developed to effectively eliminate cockroaches while ensuring compliance with industry safety standards. About Cockroach Pest Control Sydney Cockroach Pest Control Sydney is dedicated to providing high-quality pest management services across Sydney. With years of experience in the industry, the company has established itself as a trusted provider of effective pest control solutions. The team is committed to using environmentally responsible methods that protect both clients and the broader community. For more information visit us at https://cockroachpestcontrol.sydney . For media inquiries or further information about services offered by Cockroach Pest Control Sydney. Please contact: Owner/Spokesperson: Milad Bahrami Cockroach Pest Control Sydney Address: 18/321 Kent St, Sydney NSW 2000 Phone: 0420 103 048 Email: hello@cockroachcontrol.sydney [mailto:hello@cockroachcontrol.sydney] Media Contact Company Name: Cockroach Pest Control Sydney Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=effective-cockroach-pest-control-solutions-available-across-sydney-nsw ] Phone: 0420 103 048 Address:18/321 Kent St City: Sydney State: NSW 2000 Country: Australia Website: https://cockroachpestcontrol.sydney This release was published on openPR.

VALLADOLID, Spain (Reuters) – Atletico Madrid hammered bottom side Real Valladolid 5-0 in a LaLiga encounter at the Jose Zorrilla stadium on Saturday and provisionally moved into second place in the standings. Atletico are on 32 points, two ahead of Real Madrid, who have two games in hand. Barcelona, who lost 2-1 to Las Palmas earlier on Saturday, remain top with 34 points. Clement Lenglet opened the scoring for Atletico after 26 minutes with a close-range finish from Marcos Llorente’s cross from the right, marking the French defender’s first LaLiga goal since 2020. Julian Alvarez doubled the lead in the 35th minute, pouncing on a rebound from goalkeeper Karl Hein who had blocked Antoine Griezmann’s shot but could not deny the Argentine striker from the second attempt. Rodrigo De Paul made it 3-0 two minutes later with a first-time low shot, before Griezmann added another goal seven minutes into the second half after a brilliant move that drew applause from the opposing fans. Alexander Sorloth scored a stoppage-time winner as Valladolid slumped to their tenth defeat in 15 games, leaving them bottom of the table on nine points. (Reporting by Janina Nuno Rios in Mexico City; editing by Clare Fallon) Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibilty for its content. var ytflag = 0;var myListener = function() {document.removeEventListener('mousemove', myListener, false);lazyloadmyframes();};document.addEventListener('mousemove', myListener, false);window.addEventListener('scroll', function() {if (ytflag == 0) {lazyloadmyframes();ytflag = 1;}});function lazyloadmyframes() {var ytv = document.getElementsByClassName("klazyiframe");for (var i = 0; i < ytv.length; i++) {ytv[i].src = ytv[i].getAttribute('data-src');}} Save my name, email, and website in this browser for the next time I comment. Δ document.getElementById( "ak_js_1" ).setAttribute( "value", ( new Date() ).getTime() );

Even with October struggles, AL MVP Aaron Judge put up one of the greatest seasons we’ve ever seenTOWSON 64, MORGAN STATE 60